
Today on Drug Discovery & Development
Regeneron and Sonoma Bio partner to develop Treg cell therapies for autoimmune diseases
Treg cell therapies are at the forefront of a collaboration between Regeneron (Nasdaq:REGN) and privately-held Sonoma Biotherapeutics, as they work together to discover, develop, and commercialize novel therapies for autoimmune diseases. This partnership combines Regeneron’s VelociSuite technologies with Sonoma Biotherapeutics‘ expertise in gene-modified T cell (Treg) therapies. Under the terms of the agreement, Regeneron will…Dostarlimab shows promise in improving endometrial cancer treatment outcomes
Endometrial cancer, a common gynecological malignancy, leaves considerable unmet needs for patients with advanced or recurrent disease. GSK‘s (NYSE:GSK) Jemperli (dostarlimab), a PD-1 receptor antagonist, brings hope to the numerous women diagnosed with this cancer each year. As the first immunotherapy approved for patients with deficient mismatch repair (dMMR) endometrial cancer, dostarlimab has the potential…Drug Discovery and Development See More >

This RNA sensor could trigger cells to turn on a synthetic gene
Engineers at MIT designed a new way to trigger cells that could lead to targeted therapies for cancer and other diseases. Using an RNA sensor for the trigger, the researchers ensure that synthetic genes activate only in specific cells. They demonstrated that the sensor could accurately identify cells expressing a mutated version of the p53…
Sponsored Content See More >
Genomics/Proteomics See More >

Proteomics can help us realize a future of precision healthcare: Takeaways from a 2023 prediction
Clinicians are ready and eager for the future of diagnostic and prognostic models — ones that are built on proteomics. I have been feeling and hearing one key theme in 2022 – physicians are ready, even dare I say eager, to get their hands on proteomic tests and tools that better empower and equip them…
Infectious Disease See More >

This RNA sensor could trigger cells to turn on a synthetic gene
Engineers at MIT designed a new way to trigger cells that could lead to targeted therapies for cancer and other diseases. Using an RNA sensor for the trigger, the researchers ensure that synthetic genes activate only in specific cells. They demonstrated that the sensor could accurately identify cells expressing a mutated version of the p53…
Oncology See More >

Dostarlimab shows promise in improving endometrial cancer treatment outcomes
Endometrial cancer, a common gynecological malignancy, leaves considerable unmet needs for patients with advanced or recurrent disease. GSK‘s (NYSE:GSK) Jemperli (dostarlimab), a PD-1 receptor antagonist, brings hope to the numerous women diagnosed with this cancer each year. As the first immunotherapy approved for patients with deficient mismatch repair (dMMR) endometrial cancer, dostarlimab has the potential…